197 related articles for article (PubMed ID: 32841554)
21. Clinical evolution of patients treated with aripiprazole long-acting injectable: a preliminary, prospective, observational study.
García Álvarez JC; González Sánchez L; García Resa E; Bonete Llácer JM; Román Rodríguez A; Pecino Esquerdo B; Pérez Martínez E
Int J Psychiatry Clin Pract; 2020 Mar; 24(1):10-17. PubMed ID: 31933402
[No Abstract] [Full Text] [Related]
22. Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model.
Hard ML; Mills RJ; Sadler BM; Wehr AY; Weiden PJ; von Moltke L
CNS Drugs; 2017 Jul; 31(7):617-624. PubMed ID: 28597226
[TBL] [Abstract][Full Text] [Related]
23. Effect of aripiprazole on verbal memory and fluency in schizophrenic patients : results from the ESCAPE study.
Bervoets C; Morrens M; Vansteelandt K; Kok F; de Patoul A; Halkin V; Pitsi D; Constant E; Peuskens J; Sabbe B
CNS Drugs; 2012 Nov; 26(11):975-82. PubMed ID: 23018547
[TBL] [Abstract][Full Text] [Related]
24. Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole Lauroxil.
Nasrallah HA; Aquila R; Stanford AD; Jamal HH; Weiden PJ; Risinger R
Psychopharmacol Bull; 2017 Aug; 47(3):35-43. PubMed ID: 28839338
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of aripiprazole 2-month ready-to-use 960 mg: secondary analysis of outcomes in adult patients with bipolar I disorder in a randomized, open-label, parallel-arm, pivotal study.
McIntyre RS; Such P; Yildirim M; Madera-McDonough J; Zhang Z; Larsen F; Harlin M
Curr Med Res Opin; 2023 Jul; 39(7):1021-1030. PubMed ID: 37272079
[TBL] [Abstract][Full Text] [Related]
26. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
Swainston Harrison T; Perry CM
Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
[TBL] [Abstract][Full Text] [Related]
27. Aripiprazole Lauroxil: A Review in Schizophrenia.
Frampton JE
Drugs; 2017 Dec; 77(18):2049-2056. PubMed ID: 29177572
[TBL] [Abstract][Full Text] [Related]
28. Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis.
Kane JM; Zhao C; Johnson BR; Baker RA; Eramo A; McQuade RD; Duca AR; Sanchez R; Peters-Strickland T
J Med Econ; 2015 Feb; 18(2):145-54. PubMed ID: 25347448
[TBL] [Abstract][Full Text] [Related]
29. Effects of aripiprazole once-monthly on symptoms of schizophrenia in patients switched from oral antipsychotics.
Peters-Strickland T; Zhao C; Perry PP; Eramo A; Salzman PM; McQuade RD; Johnson BR; Sanchez R
CNS Spectr; 2016 Dec; 21(6):460-465. PubMed ID: 27531181
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study.
Schöttle D; Janetzky W; Luedecke D; Beck E; Correll CU; Wiedemann K
BMC Psychiatry; 2018 Nov; 18(1):365. PubMed ID: 30428862
[TBL] [Abstract][Full Text] [Related]
31. Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study.
Kwon JS; Jang JH; Kang DH; Yoo SY; Kim YK; Cho SJ;
Psychiatry Clin Neurosci; 2009 Feb; 63(1):73-81. PubMed ID: 19154213
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of aripiprazole lauroxil once-monthly versus aripiprazole once-monthly long-acting injectable formulations in patients with acute symptoms of schizophrenia: an indirect comparison of two double-blind placebo-controlled studies.
Cameron C; Zummo J; Desai D; Drake C; Hutton B; Kotb A; Weiden PJ
Curr Med Res Opin; 2018 Apr; 34(4):725-733. PubMed ID: 29179595
[TBL] [Abstract][Full Text] [Related]
33. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study.
Kane JM; Peters-Strickland T; Baker RA; Hertel P; Eramo A; Jin N; Perry PP; Gara M; McQuade RD; Carson WH; Sanchez R
J Clin Psychiatry; 2014 Nov; 75(11):1254-60. PubMed ID: 25188501
[TBL] [Abstract][Full Text] [Related]
34. Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial.
Pagsberg AK; Jeppesen P; Klauber DG; Jensen KG; Rudå D; Stentebjerg-Olesen M; Jantzen P; Rasmussen S; Saldeen EA; Lauritsen MG; Bilenberg N; Stenstrøm AD; Nyvang L; Madsen S; Werge TM; Lange T; Gluud C; Skoog M; Winkel P; Jepsen JRM; Fagerlund B; Correll CU; Fink-Jensen A
Lancet Psychiatry; 2017 Aug; 4(8):605-618. PubMed ID: 28599949
[TBL] [Abstract][Full Text] [Related]
35. A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder.
Harlin M; Yildirim M; Such P; Madera-McDonough J; Jan M; Jin N; Watkin S; Larsen F
CNS Drugs; 2023 Apr; 37(4):337-350. PubMed ID: 36961650
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial.
Chan HY; Lin WW; Lin SK; Hwang TJ; Su TP; Chiang SC; Hwu HG
J Clin Psychiatry; 2007 Jan; 68(1):29-36. PubMed ID: 17284127
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of aripiprazole once-monthly versus oral aripiprazole in Chinese patients with acute schizophrenia: a multicenter, randomized, double-blind, non-inferiority study.
Xiao L; Zhao Q; Li AN; Sun J; Wu B; Wang L; Zhang H; Zhang R; Li K; Xu X; Liu T; Zhang W; Xie S; Xu X; Tan Y; Zhang K; Zhang H; Guan N; Xian M; Uki M; Wang G
Psychopharmacology (Berl); 2022 Jan; 239(1):243-251. PubMed ID: 34989824
[TBL] [Abstract][Full Text] [Related]
38. Switching patients with schizophrenia from paliperidone palmitate to aripiprazole lauroxil: A 6-month, prospective, open-label study.
Miller BJ; Claxton A; Du Y; Weiden PJ; Potkin SG
Schizophr Res; 2019 Jun; 208():44-48. PubMed ID: 30745067
[TBL] [Abstract][Full Text] [Related]
39. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study.
Casey DE; Carson WH; Saha AR; Liebeskind A; Ali MW; Jody D; Ingenito GG;
Psychopharmacology (Berl); 2003 Apr; 166(4):391-9. PubMed ID: 12610718
[TBL] [Abstract][Full Text] [Related]
40. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study.
Kane JM; Sanchez R; Perry PP; Jin N; Johnson BR; Forbes RA; McQuade RD; Carson WH; Fleischhacker WW
J Clin Psychiatry; 2012 May; 73(5):617-24. PubMed ID: 22697189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]